SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Altchem Ltd

(Last) (First) (Middle)
CITY HOUSE
6 KARAISKAKIS STREET

(Street)
LIMASSOL G4 3032

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RVL Pharmaceuticals plc [ RVLP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/19/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 10/19/2023 S 9,363,760 D $0.0461(1) 9,700,000 D
Ordinary Shares 10/20/2023 S 4,758,899 D $0.0312(2) 4,941,101 D
Ordinary Shares 1,182,243 I By Self as Sole Manager of Orbit Co-Invest A-1 LLC(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Altchem Ltd

(Last) (First) (Middle)
CITY HOUSE
6 KARAISKAKIS STREET

(Street)
LIMASSOL G4 3032

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Orbit Co-Invest A-1 LLC

(Last) (First) (Middle)
885 3RD AVENUE
17TH FLOOR

(Street)
NEW YORK NY 10022

(City) (State) (Zip)
Explanation of Responses:
1. The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0400 to $0.0580, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0300 to $0.0373, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Represents shares of the Issuer held by Orbit Co-Invest A-1 LLC. Altchem Limited is the sole manager of Orbit Co-Invest A-1 LLC. As a result, Altchem Limited may be deemed to share voting and investment power with respect to the shares held by Orbit Co-Invest A-1 LLC. Altchem Limited disclaims beneficial ownership of such shares and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
/s/MILITSA SYMEOU, Altchem Limited, by Militsa Symeou, its Director 10/23/2023
/s/MILITSA SYMEOU, Orbit Co-Invest A-1 LLC, by Altchem Limited, its sole manager 10/23/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

RVL Pharmaceuticals (NASDAQ:RVLP)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 2월(2) 2024 RVL Pharmaceuticals 차트를 더 보려면 여기를 클릭.
RVL Pharmaceuticals (NASDAQ:RVLP)
과거 데이터 주식 차트
부터 3월(3) 2023 으로 2월(2) 2024 RVL Pharmaceuticals 차트를 더 보려면 여기를 클릭.